

Santen Receives Marketing Approval in Japan for “*PRESERFLO MicroShunt Glaucoma Drainage System Core Kit*” to Treat Glaucoma

February 28th, 2022 - Santen Pharmaceutical Co., Ltd. (Head office in Osaka; hereinafter “Santen”) today announced that it has received marketing approval in Japan for “*PRESERFLO MicroShunt Glaucoma Drainage System Core Kit* (medical device approval number 30400BZX00044000)” (hereinafter “*PRESERFLO MicroShunt*”), an intraocular drainage device. It is used in combination with the *PRESERFLO MicroShunt Glaucoma Drainage System Accessory Kit* (medical device certification number 303AIBZX00031000) for glaucoma patients who cannot bring down intraocular pressure sufficiently with treatments including medication and laser treatment.

Glaucoma is a diseases where the optic nerve is damaged, thereby causing gradual vision loss. Since the disease is generally progressive and irreversible, early detection and early treatment to control the progression of optic nerve damage and vision field defects are crucial in treatment, and lowering intraocular pressure is the most effective means of avoiding glaucomatous damage. *PRESERFLO MicroShunt* is a 8.5mm-long glaucoma filtration device composed of a copolymer called SIBS [poly (styrene-block-isobutylene-block-styrene)]. This is placed under conjunctival flap and is inserted from the limbus to anterior chamber. *PRESERFLO MicroShunt* reduces intraocular pressure through artificial bypass from anterior chamber to outside of the eye. The filtration procedure using *PRESERFLO MicroShunt* is low-invasive and simpler than trabeculectomy. Shorter procedure and simpler post-surgery management are expected, reducing burden of both patients and surgeons.

Glaucoma is a severe disease which finally causes vision loss if patients do not receive appropriate treatment. It is globally ranked high as a cause of vision loss, and is the No.1 cause of vision loss in Japan¹. It is typically treated with medication and laser treatment to control intraocular pressure. If these treatments fail to reduce intraocular pressure sufficiently, incisional surgery is performed. The most common incisional surgery for glaucoma is trabeculectomy. Its technique has been improved to enhance treatment performance, but it does not necessarily produce completely satisfactory results in terms of the rate of postoperative complications including hypotony.

Santen will provide *PRESERFLO MicroShunt* as a new treatment option, broadening treatment options for patients and contributing to improving their quality of life further.

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, and as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website (www.santen.com).

Contact

Corporate Communications Group

Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com

ⁱ Japan Glaucoma Society <https://www.ryokunaisho.jp/>